NCT03565341已完成不适用
Evaluation of the Efficacy and Safety of the PiQo4 Picosecond Laser (PSL) System for the Treatment of Patients With Melasma: A Prospective, Randomized, Split Face Study Comparing the Added Value of 585nm Over 1064nm PSL
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Percent of subjects having an improvement of at least 1 point on the MSS or ≥ 50% MASI score improvement on at least one of the face sides at the 1-month follow-up visit.
研究概览
简要总结
Single center, Prospective, Open Label with Split-face Study Design. Face sides will be randomized to receive either 1064nm alone or 1064nm & 585nm combination treatment.
Each subject will receive up to 3 treatments at monthly intervals (±4 days). Follow-up visits will take place at 1, 3, and 6 months following the last treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy Female
- •Fitzpatrick skin phototype = II-V
- •Melasma severity: diagnosed with mild to severe melasma lesions (MSS≥2)
- •Melasma type: Dermal or mixed type melasma, confirmed by Wood's lamp test
- •Melasma duration: The subject's melasma has persisted for greater than 6 months
- •Melasma previous treatments: has failed to respond to conventional treatment with hydroquinone or other topical lightening agents
- •Able to read, understand and provide written Informed Consent.
- •Able and willing to comply with the treatment/follow-up schedule and post treatment care
- •Agreed to use the same facial skin care products during the clinical trial period (including the follow-up period)
- •Agreed to the prohibition of the use of local/systemic corticosteroids or retinoids and other local/systemic lightening medications, and willing to abide by such instructions
- •Agreed to the daily use of an over SPF 50 sunblock on their face during the clinical trial period (including the follow-up period), and willing to abide by such instructions
- •Agreed to have their face photographed and willingness to allow Focus Medical (the study Sponsor) and Lumenis and the investigators to use de-identified photographs of the treated area for presentation and publication purposes
- •(In case of fertile women) Tested negative in the pregnancy test and agreed to use birth control contraceptives during the clinical trial period - Oral contraceptives are forbidden as they may influence the results of the clinical study.
- •Agreed not to undergo any other procedure on their face during their participation in the clinical trial
排除标准
- •Pregnant, intending to become pregnant during the course of study, less than 3 months postpartum or less than 3 months after completion of breastfeeding
- •Known hypersensitivity or contraindications to anaesthetic agents including lidocaine and its derivatives
- •Participation in a study of another device or drug within three months prior to enrolment or during the study.
- •Presence of open wounds or lesions in the area
- •Extensive scarring or tattoos in areas to be treated.
- •Having other pigmentation disorder
- •Having an excessive underlying vascular condition (e.g. dense network of capillaries).
- •Suffering from current or history of significant skin conditions in the treated area that could interfere with the evaluation (i.e. infection, dermatitis, or rash on their face) or requires the use of interfering topical or systemic therapy.
- •Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
- •Having a history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treated area, unless treatment is conducted following a prophylactic regimen
- •Subjects who are opposed to possible damage to the hair follicles with possible loss of hair in the treatment area
- •Laser or medium/deep chemical peel, or surgery, or filler treatments using collagen, hyaluronic acid, or any other material at area of treatment, within 6 months of initial treatment or during the course of the study.
- •IPL or superficial chemical peel within the previous 1 month
- •Topical therapy with retinoids, imiquimod, 5-fluorouracil, ingenol mebutate, diclofenac, alpha-hydroxy acids, or salicylic acids within the previous 1 month.
- •Currently using topical retinoid, hydroquinone or corticosteroid or whitening cream such as alpha arbutin, azelaic acid, kojic acid ascorbic acid or any cosmetics within 2 weeks
- •Lightening oral medication (hydroquinone, tranexamic acid), isotretinoid (or retinoid), light-sensitive medication, or steroids in the last 6 months
- •History of keloid scarring, hypertrophic scarring, or of abnormal wound healing.
- •History of connective tissue diseases such as systemic lupus erythematosus or scleroderma
- •Active leukoplakia, eczema, or psoriasis in the treatment area
- •History of post inflammatory pigmentary disorders, particularly a tendency for hyper- or hypo-pigmentation.
- •History of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis.
- •Has used photosensitizing drugs (e.g., Declomycin, sulfa antibiotics, phenothiazines, etc.) within a timeframe where photosensitization from these drugs may still be present
- •History of skin cancer in the treatment area
- •Significant concurrent illness or any disease state that in the opinion of the Investigator would interfere with the treatment or healing process
- •History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
- •Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician's discretion).
- •History of hormonal therapy in the last 3 months (e.g., estrogen, progesterone, or oral contraceptive)
- •As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study
结局指标
主要结局
Percent of subjects having an improvement of at least 1 point on the MSS or ≥ 50% MASI score improvement on at least one of the face sides at the 1-month follow-up visit.
时间窗: 1 month follow up
The study will be deemed successful if the point estimate of the percent of successful subjects will be at least 50%.
次要结局
- Percent of subjects having an improvement of at least 1 point on the MSS or ≥ 50% MASI score improvement on at least one of the face sides at the 3-month follow-up visit(3 months follow up)
- Percent of subjects having an improvement of at least 1 point on the MSS or ≥ 50% MASI score improvement on each face side(6 months follow up)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
4 期
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene TherapyMuscular Atrophy, SpinalNCT05861999Hoffmann-La Roche28
招募中
4 期
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene TherapyMuscular Atrophy, SpinalNCT05861986Hoffmann-La Roche28
进行中（未招募）
3 期
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple SclerosisProgressive Multiple Sclerosis (PMS)NCT03523858Hoffmann-La Roche927
已完成
4 期
Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).Metastatic Colorectal CancerNCT03564938Bayer100
已完成
不适用
Correlation Study Between PEST and SCORAD in Management of Atopic Dermatitis With Ceradan® RegimenAtopic DermatitisNCT02073591Hyphens Pharma Pte Ltd58